Nagendran Sukumar's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed Dec 1, 2025
- Accession no.
- 0001665124-25-000003
- Filed
- Dec 1, 2025
- Trade date
- Nov 28-Dec 1, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.70M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nagendran SukumarCIK 0001665124 | Director, Officer (President and Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Common Stock | MOption exerciseAcquired | +70,172 | $0.70 | +$49,120.4 | 1,076,611 | Direct | |
| Nov 28, 2025 | Common Stock | MOption exerciseAcquired | +39,953 | $1.71 | +$68,319.63 | 1,116,564 | Direct | |
| Nov 28, 2025 | Common Stock | SSaleDisposed | −110,125 | $4.75 | −$523,093.75 | 1,006,439 | Direct | |
| Dec 1, 2025 | Common Stock | MOption exerciseAcquired | +260,047 | $1.71 | +$444,680.37 | 1,266,486 | Direct | |
| Dec 1, 2025 | Common Stock | SSaleDisposed | −260,047 | $4.51 | −$1,172,811.97 | 1,006,439 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Common Stock | MOption exerciseDisposed | −70,172 | $0.00 | $0 | 222,683 | Direct | |
| Nov 28, 2025 | Common Stock | MOption exerciseDisposed | −39,953 | $0.00 | $0 | 823,664 | Direct | |
| Dec 1, 2025 | Common Stock | MOption exerciseDisposed | −260,047 | $0.00 | $0 | 563,617 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.